References
- Lamictal® (lamotrigine) Tablets prescribing information. Glaxo-SmithKline, September 2006
- Cohen AF, Land GS, Briemer DD, et al. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal man. Clin Pharmacol Ther 1987;42:535–41
- Magdalou J, Herber R, Bidault R, et al. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 1992;260:1166–73
- Rowland A, Elliot DJ, Williams JA, et al. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab Dispos 2006;34:1055–62
- Morris RG, Black AB, Lam E, et al. Clinical study of lamotrigine and valproic acid in patients with epilepsy: Using a drug interaction to advantage? Ther Drug Monit 200;22:656–60
- Sale ME, Natarajan S, Biton V, et al. A dosing algorithm for con verting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy. Epilepsy Behav 2005;6:63–70
- Gidal BE, Sheth R, Parnell J, et al. Evaluation of VPA dose and concentration effects on lamotrigine: implications for conversion to lamotrigine monotherapy. Epilepsy Res 2003;57:85–93
- Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998;51:1018–25
- Frank LM, Enlow T, Holmes GL, et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia 1999;40:973–9
- Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;345:376–9
- Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65:1737–43